NRXCF - NeutriSci International Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0742
-0.0072 (-8.85%)
At close: 12:35PM EST
Stock chart is not supported by your current browser
Previous Close0.0814
Open0.0728
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0728 - 0.0742
52 Week Range0.0530 - 0.2705
Volume11,500
Avg. Volume32,992
Market Cap8.731M
Beta (3Y Monthly)3.22
PE Ratio (TTM)N/A
EPS (TTM)-0.0170
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswirelast month

    Neutrisci International and Nutritional High Announce Production and Distribution Update

    NeutriSci International Inc. ("NeutriSci") (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) the innovator and pioneer behind neuenergy® and Nutritional High International Inc. (“Nutritional High”) (CSE: EAT, OTCQB: SPLIF, FRANKFURT: 2NU) are pleased to provide a further update on their previously announced partnership. The initial production run for the newly developed chewable, sublingual cannabis product (“NU Tablets”) for distribution and sale in the state of California, is on track and underway at Nutritional High's FLI NorCal facility in Sacramento, California.  Delivery of the first purchase orders are set for November 2018. Initial distribution by Nutritional High's distributor, Calyx, will begin to approximately 450 plus dispensaries across the state of California.  Unveiling of the finished packaging and branding will be released prior to the first shipment to dispensaries.

  • GlobeNewswirelast month

    NeutriSci and Naturally Splendid USA Announce Expanded Binding Terms of Partnership and Added Distribution of HempOmega™ and Cannabidiol (CBD) Sublingual Tablets

    NeutriSci International Inc. (the "Company" or "NeutriSci") (TSX-V: NU, OTCQB: NRXCF, Frankfurt: 1N9) is pleased to provide a further update on its previously announced non-binding letter of intent (“LOI”) between the Company and Naturally Splendid USA Ltd. ("Naturally Splendid") (TSX-V: NSP, OTCQB: NSPDF). This new binding LOI signifies the successful completion of a sublingual HempOmega® tablet using NeutriSci’s IP and technology, as well as a sublingual tablet combining HempOmega® and CBD (cannabidiol). A definitive agreement between the parties will follow in the coming weeks.

  • GlobeNewswirelast month

    Naturally Splendid USA and NeutriSci Announce Expanded Binding Terms of Partnership and Added Distribution of HempOmega™ and Cannabidiol (CBD) Sublingual Tablets

    NATURALLY SPLENDID ENTERPRISES LTD. (NSP.V)(NSPDF) (“Naturally Splendid” or “NSE” or the “ Company” or “Naturally Splendid USA”) is pleased to provide a further update on its previously announced non-binding Letter of Intent (“LOI”) between Naturally Splendid USA Ltd. and NeutriSci International Inc. ("NeutriSci") (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9), together the (“Parties”). Naturally Splendid USA and NeutriSci are pleased to announce the extension and addition of binding terms to the previously announced LOI. This new binding LOI signifies the successful completion of an agreement to produce a sublingual HempOmega® tablet using NeutriSci’s IP and technology, as well as a sublingual tablet combining HempOmega® and CBD (cannabidiol).

  • Newsfile9 months ago

    Neutrisci Files Patent Application

    Vancouver, British Columbia--(Newsfile Corp. - March 1, 2018) - NeutriSci International Inc. (TSXV: NU) (OTCQB: NRXCF) (FSE: 1N9) (the "Company" or "NeutriSci")  the innovator and pioneer behind neuenergy®, is pleased to announce the filing of a new U.S. provisional patent application (United States Provisional Patent No. 62/628,735; Compositions Comprising Co-crystals of Stilbenoids and Cannabinoids) relating to compositions comprising pterostilbene and other stilbenoids in formulations which improve the dissolution rate and bioavailability of cannabinoid compounds.Cannabinoids ...

  • Newsfile9 months ago

    Neutrisci and Lexaria Bioscience Enter Global Licensing Agreement

    Vancouver, British Columbia--(Newsfile Corp. - February 26, 2018) - NeutriSci International Inc. (TSXV: NU) (OTCQB: NRXCF) (FSE: 1N9) (the "Company" or "NeutriSci") and Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) ("Lexaria") are pleased to announce that they have revised their joint venture agreement such that NeutriSci now owns 100% of Ambarii Trade Corporation ("Ambarii"), and Lexaria has granted to NeutriSci, an Intellectual Property License and Supply Agreement (the "License Agreement") for the manufacturing and sale of CBD ...

  • ACCESSWIRE9 months ago

    Lexaria and Neutrisci Enter Global Licensing Agreement

    KELOWNA, BRITISH COLUMBIA / ACCESSWIRE / February 26, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria") a drug delivery platform innovator, announces ...

  • Marketwired10 months ago

    NeutriSci Announces Major Sponsorship With Tennis Star Genie Bouchard

    NeutriSci International Inc. , the innovator and pioneer behind neuenergy®, is pleased to announce a one-year sponsorship deal with Canadian and International tennis...

  • Newsfile10 months ago

    Neutrisci Announces a Major R&D MOU with Scientus Pharma to Develop a Medical Cannabinoid Retail Product

    Vancouver, British Columbia--(Newsfile Corp. - January 8, 2018) - NeutriSci International Inc. (TSXV: NU) (OTCQB: NRXCF) (FSE: 1N9) (the "Company" or "NeutriSci"), the innovator and pioneer behind neuenergy®, is pleased to announce it has entered into a major R&D Memorandum of Understanding with Scientus Pharma Inc. ("Scientus Pharma"). Under the terms of the MOU, both companies have agreed to share their technologies to develop, test, produce, and distribute a medical cannabinoid product for existing ...